| Literature DB >> 19693267 |
Brian E Roe1, Michael R Tilley, Howard H Gu, David Q Beversdorf, Wolfgang Sadee, Timothy C Haab, Audrey C Papp.
Abstract
With recent advances in understanding of the neuroscience of risk taking, attention is now turning to genetic factors that may contribute to individual heterogeneity in risk attitudes. In this paper we test for genetic associations with risk attitude measures derived from both the psychology and economics literature. To develop a long-term prospective study, we first evaluate both types of risk attitudes and find that the economic and psychological measures are poorly correlated, suggesting that different genetic factors may underlie human response to risk faced in different behavioral domains. We then examine polymorphisms in a spectrum of candidate genes that affect neurotransmitter systems influencing dopamine regulation or are thought to be associated with risk attitudes or impulsive disorders. Analysis of the genotyping data identified two single nucleotide polymorphisms (SNPs) in the gene encoding the alpha 4 nicotine receptor (CHRNA4, rs4603829 and rs4522666) that are significantly associated with harm avoidance, a risk attitude measurement drawn from the psychology literature. Novelty seeking, another risk attitude measure from the psychology literature, is associated with several COMT (catechol-O-methyl transferase) SNPs while economic risk attitude measures are associated with several VMAT2 (vesicular monoamine transporter) SNPs, but the significance of these associations did not withstand statistical adjustment for multiple testing and requires larger cohorts. These exploratory results provide a starting point for understanding the genetic basis of risk attitudes by considering the range of methods available for measuring risk attitudes and by searching beyond the traditional direct focus on dopamine and serotonin receptor and transporter genes.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19693267 PMCID: PMC2724734 DOI: 10.1371/journal.pone.0006704
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Spearman Rank Correlation Coefficients Among Tasks.
| NS | HA | SGL | SGG | Summary Statistics | |
| Novelty Seeking | 1.000 | 0.437 | |||
| (NS) | – | – | – | – | 0.013 |
| 64 | (0.179, 0.736) | ||||
| Harm Avoidance | -0.411 | 1.000 | 0.426 | ||
| (HA) | 0.004 | – | – | – | 0.018 |
| 64 | 64 | (0.135, 0.763) | |||
| % Safe Gambles – Large Stakes | -0.063 | 0.006 | 1.000 | 0.387 | |
| (SGL) | 0.997 | 1.000 | – | – | 0.020 |
| 64 | 64 | 66 | (0, 0.667) | ||
| % Safe Gambles – Gains | -0.066 | -0.179 | 0.886 | 1.000 | 0.403 |
| (SGG) | 0.996 | 0.642 | <0.001 | – | 0.019 |
| 64 | 64 | 66 | 66 | (0.056, 0.778) |
Each cell in the first 4 columns of numbers lists the Spearman rank correlation coefficient, Sidak adjusted p-value and number of observations, respectively. Each summary statistic cell lists mean, standard error, minimum and maximum observation, respectively.
List of SNPs Analyzed.
| Gene | SNP | |
|
| Cholinergic receptor, nicotinic, alpha 4 | rs755203, rs1044393, rs1044397 |
|
| Catechol- | rs4633, rs4680 |
|
| D-amino acid oxidase | rs2070588, rs3741775, rs3825251, rs3918347, rs7980427 |
|
| Dopamine transporter | rs6347 |
|
| Disrupted-in-Schizophrenia 1 | rs823163, rs913730, rs1000731, rs3738401 |
|
| Dopamine receptor D2 | rs6277, rs6279, rs1079595, rs1124493, rs1125394, rs1800497 |
|
| Dopamine receptor D3 | rs6280, rs226082, rs963468, rs2134655 |
|
| Estrogen receptor alpha | rs827421, rs988328, rs1801132, rs2228480, rs3798577 |
|
| Serotonin receptor subtype 2A | rs6313, rs2070039, rs2246127 |
|
| Monoamine oxidase A | rs6323 |
|
| Monoamine oxidase B | rs17462, rs3027452 |
|
| Norepinephrine transporter | rs3081, rs5569, rs15534, rs36017, rs40434, rs998424, rs2242446, rs2242447, rs2279805 |
|
| Serotonin transporter | r140701, r1872924, r2020934, r3783594, r3794808 |
|
| Tyrosine hydroxylase | rs6356, rs6357, rs2070762, rs4074905 |
|
| Tryptophan hydroxylase 2 | rs4290270, rs7305115 |
|
| Vesicular Monoamine Transporter 2 | rs14240, rs36339, rs363333, rs363343, rs929493, rs1860404 |
SNPs that fail screening criteria for HE equilibrium and sufficient minor allele frequency.
List of Variable Number of Tandem Repeats Analyzed.
| Gene | Repeat Groupings | |
|
| Dopamine transporter | 9, 10 or more |
|
| Estrogen receptor alpha | 18 or fewer, 19 or more |
|
| Monoamine oxidase A | 3, 4 |
Harm Avoidance Scores by CHRNA4 rs4522666 SNP.
| Genotype | Mean | Std. Error | Count |
| C/C: | 0.568 | 0.042 | 10 |
| C/T: | 0.404 | 0.023 | 29 |
| T/T: | 0.393 | 0.027 | 25 |
Harm Avoidance Scores by CHRNA4 rs4603829 SNP.
| Genotype | Mean | Std. Error | Count |
| G/G: | 0.561 | 0.037 | 10 |
| A/G: | 0.431 | 0.024 | 30 |
| A/A: | 0.373 | 0.027 | 21 |
| Unknown: | 0.291 | 0.087 | 3 |
SNP Associations with Uncorrected P-values ≤ 0.05.
| Marker | P-Value | F-Stat | d.f. | FDR | Minor Allele Frequency |
|
| |||||
|
| 0.013 | 6.484 | 62 | 1.000 | 0.484 |
|
| 0.016 | 6.180 | 60 | 0.660 | 0.371 |
|
| 0.025 | 5.244 | 63 | 0.711 | 0.492 |
|
| 0.026 | 5.214 | 57 | 0.549 | 0.246 |
|
| 0.030 | 4.915 | 63 | 0.508 | 0.300 |
|
| 0.043 | 4.265 | 63 | 0.602 | 0.292 |
|
| 0.044 | 4.256 | 59 | 0.522 | 0.361 |
|
| 0.049 | 4.035 | 63 | 0.516 | 0.346 |
|
| |||||
|
| 0.001 | 11.033 | 63 | 0.137 | 0.154 |
|
| 0.021 | 5.574 | 63 | 0.981 | 0.500 |
|
| |||||
|
| 0.018 | 5.894 | 62 | 0.507 | 0.430 |
|
| 0.038 | 4.488 | 63 | 0.800 | 0.385 |
|
| 0.044 | 4.206 | 63 | 0.622 | 0.223 |
|
| |||||
|
| 0.014 | 6.316 | 64 | 1.000 | 0.189 |
|
| 0.017 | 5.953 | 64 | 0.804 | 0.212 |
|
| 0.026 | 5.243 | 59 | 0.786 | 0.238 |
|
| 0.033 | 4.755 | 65 | 0.755 | 0.299 |
|
| 0.048 | 4.086 | 63 | 0.728 | 0.238 |
|
| |||||
|
| 0.036 | 4.598 | 65 | 1.000 | 0.493 |
|
| 0.041 | 4.359 | 64 | 1.000 | 0.386 |
|
| 0.048 | 4.050 | 65 | 1.000 | 0.224 |
|
| |||||
|
| 0.006 | 8.165 | 64 | 0.529 | 0.189 |
|
| 0.036 | 4.578 | 64 | 1.000 | 0.212 |
p-value adjusted for False Discover Rate associated with multiple comparisons.